Edition:
United Kingdom

Capricor Therapeutics Inc (CAPR.OQ)

CAPR.OQ on NASDAQ Stock Exchange Capital Market

0.56USD
8:00pm GMT
Change (% chg)

$-0.02 (-2.83%)
Prev Close
$0.58
Open
$0.56
Day's High
$0.58
Day's Low
$0.55
Volume
24,142
Avg. Vol
40,654
52-wk High
$1.82
52-wk Low
$0.31

Latest Key Developments (Source: Significant Developments)

Capricor Resumes Dosing Of Enrolled Patients In Hope-2 Clinical Trial For Duchenne Muscular Dystrophy
Wednesday, 6 Feb 2019 

Feb 6 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR RESUMES DOSING OF ENROLLED PATIENTS IN HOPE-2 CLINICAL TRIAL FOR DUCHENNE MUSCULAR DYSTROPHY.CAPRICOR THERAPEUTICS - TO REDUCE EXPENSES & BETTER ALIGN RESOURCES, PERSONNEL ON CORE LEAD PROGRAMS, CO HAS REDUCED STAFF BY 21 FULL-TIME EMPLOYEES.CAPRICOR THERAPEUTICS - REDUCTION IN OPERATING EXPENSES IS EXPECTED TO EXTEND CO'S CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES INTO LATE 2019.CAPRICOR THERAPEUTICS - ADDITIONALLY, CO IS EXPLORING STRATEGIC ALTERNATIVES, WITH RESPECT TO ONE OR MORE OF ITS PRODUCT CANDIDATES.CAPRICOR THERAPEUTICS - U.S. FDA AND DATA AND SAFETY MONITORING BOARD HAVE GRANTED PERMISSION TO RESUME ENROLLMENT IN HOPE-2 STUDY.CAPRICOR THERAPEUTICS-ENROLLMENT OF NEW PATIENTS IN HOPE-2 TRIAL TO DEPEND ON VARIOUS FACTORS BUT TO NOT COMMENCE UNTIL ADDITIONAL FUNDING IS SECURED.  Full Article

Capricor Therapeutics Inc Files For Mixed Shelf Of Upto $75 Mln
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR THERAPEUTICS INC FILES FOR MIXED SHELF OF UPTO $75 MILLION - SEC FILING.  Full Article

Capricor Therapeutics Appoints Anthony Bergmann As CFO, Eff Jan 1, 2018 - SEC Filing
Friday, 22 Dec 2017 

Dec 22 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR THERAPEUTICS INC SAYS HAS APPOINTED ANTHONY BERGMANN AS CHIEF FINANCIAL OFFICER, EFFECTIVE JANUARY 1, 2018 - SEC FILING.CAPRICOR THERAPEUTICS INC - ON DEC 20, LELAND GERSHELL GAVE NOTICE OF HIS RESIGNATION AS CHIEF FINANCIAL OFFICER OF COMPANY, EFFECTIVE JANUARY 1, 2018.  Full Article

Capricor & California Institute For Regenerative Medicine​ Entered Into Amendment 3 To CIRM Notice Loan Award
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR SAYS ‍ON DEC 11, CO, CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE​ ENTERED INTO AMENDMENT NO. 3 TO CIRM NOTICE OF LOAN AWARD - SEC FILING.CAPRICOR SAYS PURSUANT TO AMENDMENT, TOTAL LOAN BALANCE UNDER LOAN AWARD FORGIVEN BY CIRM, TERMINATING UNIT, CO'S OBLIGATION TO REPAY LOAN BALANCE​.CAPRICOR - ‍DECISION TO TERMINATE LOAN AWARD AND FORGIVE LOAN BALANCE WAS DUE TO ABANDONMENT OF ALLSTAR PROJECT AT END OF PROJECT PERIOD​.  Full Article

Capricor Therapeutics Says FDA Cleared IND Application For CAP-1002
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR CAP-1002.CAPRICOR THERAPEUTICS INC - POTENTIAL REGISTRATION TRIAL IN DUCHENNE MUSCULAR DYSTROPHY ON TRACK TO INITIATE IN Q1 OF 2018.CAPRICOR THERAPEUTICS-PLANS TO APPLY FOR REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION FOR CAP-1002 BASED ON UPDATED GUIDANCE RECENTLY ISSUED BY FDA.  Full Article

Capricor Therapeutics reports Q3 loss per share $0.12
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Capricor Therapeutics Inc ::Capricor Therapeutics reports third quarter 2017 financial results and provides update on duchenne muscular dystrophy development program.Q3 loss per share $0.12.  Full Article

UPDATE 1-U.S. drug developer Capricor places Duchenne drug trial on hold

Dec 26 Capricor Therapeutics Inc said on Wednesday it had put on hold a clinical trial of its drug to treat Duchenne muscular dystrophy (DMD), a muscle-wasting disorder, citing a safety review.